BACKGROUND: Multidisciplinary management of head and neck cancer (HNC) must reconcile increasingly sophisticated subspecialty care with timeliness of care. Prior studies examined the individual effects of delays in diagnosis-to-treatment interval, postoperative interval, and radiation interval but did not consider them collectively. The objective of the current study was to investigate the combined impact of these interwoven intervals on patients with HNC. METHODS: Patients with HNC who underwent curative-intent surgery with radiation were identified in the National Cancer Database between 2004 and 2013. Multivariable models were constructed using restricted cubic splines to determine nonlinear relations with overall survival. RESULTS: Overall, 15,064 patients were evaluated. After adjustment for covariates, only prolonged postoperative interval (P <.001) and radiation interval (P <.001) independently predicted for worse outcomes, whereas the association of diagnosis-to-treatment interval with survival disappeared. By using multivariable restricted cubic spline functions, increasing postoperative interval did not affect mortality until 40 days after surgery, and each day of delay beyond this increased the risk of mortality until 70 days after surgery (hazard ratio, 1.14; 95% confidence interval, 1.01-1.28; P 5.029). For radiation interval, mortality escalated continuously with each additional day of delay, plateauing at 55 days (hazard ratio, 1.25; 95% confidence interval, 1.11-1.41; P <.001). Delays beyond these change points were not associated with further survival decrements. CONCLUSIONS: Increasing delays in postoperative and radiation intervals are associated independently with an escalating risk of mortality that plateaus beyond certain thresholds. Delays in initiating therapy, conversely, are eclipsed in importance when appraised in conjunction with the entire treatment course. Such findings may redirect focus to streamlining those intervals that are most sensitive to delays when considering survival burden. Cancer
INTRODUCTION
Advances in subspecialty head and neck cancer care have led to increased complexities in execution. Multidisciplinary evaluation, modern surgical reconstruction, and sophisticated radiation planning have individually improved outcomes, [1] [2] [3] but at the potential cost of lengthy delays. Timeliness of care has become progressively difficult to reconcile, 4 as delays in 1 phase often cascade into disruption of another. For example, comprehensive treatment planning may engender stage progression, extended surgical recovery may postpone adjuvant radiation, and systemic therapy may trigger toxicities that precipitate treatment breaks. All such scenarios unintentionally may result in poor oncologic outcomes.
Prior studies explored diagnosis-to-treatment interval (DTI), 5, 6 postoperative interval, 7, 8 or radiation interval 9 but did not consider them collectively. Delays in each interval individually may worsen prognosis, but their comparable importance and magnitude of effect remain poorly defined. In addition, the impact of treatment interval prolongation likely has a complex, multidimensional relation with survival, which is rarely considered. In the current study, we examined the relative impact of these interwoven treatment intervals on patients with head and neck cancer who completed definitive surgery with full-course radiation, modeling treatment intervals as continuous, nonlinear functions.
MATERIALS AND METHODS

Data Source
Data were acquired from the National Cancer Database (NCDB), a tumor registry maintained by the American Cancer Society and the Commission on Cancer of the American College of Surgeons. The NCDB records data from more than 1500 hospitals, capturing roughly 70% of all cancers treated in the United States. All current NCDB head and neck cancer participant user files were evaluated, covering patients who were diagnosed between 2004 and 2013. This study was deemed exempt by the Cedars-Sinai Institutional Review Board.
Patient Selection
Adult patients with biopsy-proven head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, larynx, and hypopharynx (International Classification of Diseases, 3rd edition codes 8050-8054) were identified (Supporting Fig. 1 ). To avoid confounding effects of subtherapeutic regimens, we focused strictly on patients who completed curative-intent surgery and full-course adjuvant radiation. Patients who had incomplete staging, treatment, or follow-up data were excluded along with those who had clinical or pathologic distant metastasis.
Patients who underwent definitive surgery >365 days after diagnosis or who did not undergo definitive surgery were excluded. To eliminate those who did not complete a full course of radiation, the following criteria were required: a minimum radiation dose of 59.4 Gy in a minimum of 30 fractions and a minimum radiation interval of 40 days (the equivalent of 6 weeks of radiation treatment). Patients who received systemic therapy >14 days before or after starting radiation were excluded to eliminate atypical chemotherapy regimens. If it was unknown whether patients had received systemic therapy, then they were excluded. Patients who had unknown, zero, or negative time intervals (DTI, postoperative interval, or radiation treatment interval) were excluded, and a minimum postoperative interval of 14 days was required. To avoid early recurrences because of delayed radiation, patients who had a postoperative interval >180 days were excluded. DTI was defined as the time from diagnosis until surgery, postoperative interval was defined as the window from surgery to the first day of radiation, and radiation interval was defined as the time from the first to the last day of radiation. Treatment package time was defined as the sum of postoperative and radiation intervals.
Statistical Methods
A missing data mechanism for variables that had missing values-race, insurance, income, education, urban/rural, great circle distance, ENE and margins (missing rates: 35.1% for ENE; 13.8% for urban/rural; and 0.9%-3.4% for others) was used according to the method proposed by Little. 10 We observed that data were not missing completely at random. To reduce the chance of bias from missing data, missing values were imputed using fully conditional specification implemented by the multivariate imputation by chained equations algorithm under the missing-at-random assumption. 11 We generated 30 complete data sets, which were analyzed separately, and then combined the results using the formula described by Rubin. 12 Univariate associations between variables were examined with the Wilcoxon rank-sum test for continuous variables and the chi-square test for categorical variables. The primary outcome was overall survival (OS), which was calculated from diagnosis to the date of death or was censored at the last follow-up. The median followup was calculated using the reverse Kaplan-Meier method. 13 Survival functions were estimated with the Kaplan-Meier method and compared using a log-rank test.
14 Univariate and multivariable survival analyses were carried out using a Cox proportional-hazards model. 15 Multivariable analyses were performed using a stepwise variable-selection procedure based on the Akaike Information Criterion (AIC). 16 Multivariable models with the lowest AIC values were selected as final models. The proportional-hazards assumption was assessed graphically and analytically with scaled Schoenfeld residuals. 17 The set S of covariates included in the multivariable model were common to all models fitted to the 30 imputed data sets. Each multivariable model from the 30 imputed data sets had between 0 and 1 additional covariate to the list in the set S. Likelihood-ratio tests were carried out to compare each full model with the reduced model that has the set S of covariates, and the results were not statistically significant.
Cancer
Postoperative interval, radiation interval, and DTI; radiation dose; and age were modeled using restricted cubic spline functions, allowing for their nonlinear associations with OS. The optimal number of knots was chosen based on the lowest AIC, and knots were placed at fixed percentiles of each variable (ie, the 10th, 50th, and 90th percentiles for 3 knots; the 5th, 35th, 65th, and 95th percentiles for 4 knots; and the 5th, 27.5th, 50th, 72.5th, and 95th percentiles for 5 knots). 18 Consequently, 3 knots were placed at 60, 63, and 70 days for the radiation dose; 4 knots were placed at 28, 43, 55, and 93 days for postoperative interval, at 41, 45, 50, and 65 days for radiation interval, and at 7, 23, 37, and 76 days for DTI; and 5 knots were placed at 42, 53, 59, 66, and 78 years for age. Estimated associations were illustrated with smoothed, restricted cubic spline plots of the natural logarithm of the adjusted hazard ratio (HR) versus postoperative and radiation intervals, with 14 and 40 as the reference levels, respectively. HRs were was estimated using a Cox proportional-hazards model adjusted with 5 knots for age and with 3 knots for sex, region, insurance status, income, Charlson/Deyo comorbidity index, transfer to an academic facility, tumor site, American Joint Committee on Cancer (AJCC) tumor (T) classification, AJCC lymph node (N) classification, extranodal extension, margin status; postoperative chemotherapy, and radiation dose. Change points in postoperative and radiation intervals were further estimated using piecewise linear regression models. 19 Statistical analyses were performed using SAS version 9.4 (SAS Institute, Inc, Cary, NC) and R version 3.4.1 (mice, rms, survival, segmented libraries; R Foundation for Statistical Computing, Vienna, Austria) with 2-sided tests and a significance level of .05. 
RESULTS
Patient Cohort
In total, 15,064 patients met the inclusion criteria (Supporting Fig. 1 ). The median follow-up was 54.3 months (95% confidence interval [CI], 53.6-55.2 months). The mean 6 standard deviation (SD) DTI was 34.5 6 24.2 days, the mean 6 SD postoperative interval was 52.9 6 21.0 days, and the mean 6 SD radiation interval was 49.8 6 12.2 days (Fig. 1 , Supporting Table 1 ).
Treatment Intervals
In univariate analysis, all 3 treatment intervals were associated significantly with mortality (P < .001) ( Table 1) . After adjustment for covariates, DTI fell out of the model and held no prognostic value ( Fig. 2A,B, Supporting Fig.  2 ), whereas prolonged postoperative (P < .001) and radiation (P < .001) intervals retained strong associations with worse OS (Fig. 2C-F) . Given their nonlinear relation, restricted cubic spline functions were used to model the relation between treatment interval and survival (Table 2 ). For postoperative interval, a reference level was set at 14 days (defined as the minimum recovery period before starting adjuvant radiation). No significant detriment was observed up to 40 days after surgery. However, the risk of mortality beyond this time point escalated with each day of delay (HR, 1.004; 95% CI, 1.000-1.008; P 5 .029), plateauing at 70 days (HR, 1.14 for a 30-day increment; 95% CI, 1.01-1.28; P 5 .029) (Fig. 3A) . Further postoperative delays did not appear to worsen the risk of death. The estimated 5-year OS rates for the subgroups that had delays <40 days, from 40 to 70 days, and >70 days were 66.5%, 56.8%, and 50.0%, respectively.
For radiation interval, a reference level was set at 40 days (equivalent to a therapeutic 6-week course of adjuvant radiation). The risk of death increased continuously with each day of delay (HR, 1.016; 95% CI, 1.007-1.025; P < .001), up to a change point of 55 days (HR, 1.25 for a 14-day increment; 95% CI, 1.11-1.41; P < .001) (Fig.  3B) . Further prolongation of the radiation interval had no additional impact on survival. The estimated 5-year OS rates for the subgroups that had delays<55 days and 55 days were 59.9% and 50.8%, respectively.
Although postoperative and radiation intervals were evaluated as independent variables, they are often considered compositely as treatment package time. We further investigated the window of negative impact, if any, in this compound interval, with a reference level set at 54 days (a minimum 14-day postoperative interval with a minimum 40-day radiation interval). No significant mortality risk was noted if treatment was completed within 84 days of surgery (Supporting Fig. 3) . However, the risk of mortality increased with each day of delay beyond 84 days (HR, 1.007; 95% CI, 1.004-1.010; P < .001), plateauing at 122 days (HR, 1.28 for a 38-day increment; 95% CI, 1.15-1.44; P < .001). Further delays did not appear to worsen the risk of death. The subgroups that had delays <84 days, from 84 to 122 days, and >123 days comprised 16.7%, 68.1%, and 15.2% of patients, respectively, and their estimated 5-year OS rates were 70.0%, 57.7%, and 47.9%, respectively (Supporting Fig. 4) .
Because prolonged DTI was not associated with survival, we explored additional factors influenced by treatment initiation delays that might secondarily affect mortality. A subgroup analysis was performed among patients who had early stage disease (T1-T2N0) to assess whether stage progression caused by such delays conferred undue risk. In this cohort, DTI remained nonsignificant on multivariable analysis, whereas postoperative and radiation intervals remained significant (Supporting Table 2 ). Similar results were observed in a subgroup analysis of patients who had human papillomavirus-positive oropharyngeal cancer (Supporting Table 3 ).
DISCUSSION
In the current analysis, we examined the collective impact of treatment intervals from diagnosis to therapy completion on patients with head and neck cancer who underwent surgery and received adjuvant radiation. By using a granular multivariable approach, we demonstrated progressively worsening outcomes with escalating delays in both postoperative and radiation intervals, but only during specific windows of time. For postoperative interval, mortality risk began to increase beyond 5.7 weeks after surgery, plateauing at 10 weeks; for radiation interval, mortality risk began increasing immediately with any delay, plateauing at 7.9 weeks from the start of radiation. The cumulative risk of mortality noted at these thresholds indicates that such delays are important surrogates for a poor prognosis: their values are roughly comparable to the hazard conferred by classic adverse factors like positive margin status (HR, 1.28; 95% CI, 1.20-1.36) or extranodal extension (HR, 1.34; 95% CI, 1.15-1.56). Unlike these inflexible, tumor-intrinsic elements, it is compelling that treatment interval factors are potentially modifiable. Disturbingly, only 16.7% of patients in the current study had a composite treatment package time 83 days, which is the minimum threshold before mortality risk began to rise, and even fewer patients were able to complete therapy on time (by 54 days). Thus, minimizing treatment delay remains a formidable yet targetable area for improving the outcomes of patients with head and neck cancer. It is noteworthy that we restricted our analysis only to ideal patients who underwent curativeintent surgery and completed a full course of radiation: patients who received subtherapeutic, incomplete, or truncated treatment regimens may be expected to do far worse.
The execution of multimodality care for patients with head and neck cancer is often undermined by the practical realities of treatment. Factors like travel logistics, postsurgical recovery, treatment complications, lack of supportive ancillary services, and poor performance status may produce delays in overall treatment time. These delays, in turn, influence survival through established biologic mechanisms involving accelerated repopulation of remnant cancer cells, diminishing radiation efficacy, and breeding tumor radioresistance. 20, 21 The National Comprehensive Cancer Network guidelines 22 recommend a postoperative interval <6 weeks based on a meta-analysis of studies that arbitrarily selected this threshold based on poorer locoregional control. 23 Others have emphasized a treatment package time of approximately 100 days. 7, 24 Although our results support these cutoff points, they also quantify a continuum of risk using an agnostic cutoff point evaluation, with no detriment to survival observed if radiation was initiated within 40 days of surgery. This naturally coincides with a reasonable window for healing after surgery. Conversely, any prolongation of the radiation interval appears to adversely affect survival, worsening well beyond the binary thresholds currently defined in guidelines. Finally, incremental mortality risk plateaus with each interval, suggesting that colossal delays are less consequential: the damage is already done.
Although prolonged DTI was associated with worse survival when considered in isolation, its prognostic value disappeared in multivariable analysis when examined in combination with postoperative and radiation intervals. Our analysis helps clarify the conflicting body of literature surrounding the relevance of DTI. Prior studies have failed to consistently identify an effect from DTI delays, including in head and neck, pancreatic, lung, breast, colorectal, and pancreatic malignancies. [25] [26] [27] [28] Although a meaningful percentage of patients with HNSCC exhibit volumetric progression with delay before surgery, 29, 30 it is unclear whether this translates into worsened outcomes. 31 One analysis of patients with HNSCC who received treatment between 2003 and 2005 detected a relation with delayed DTI and decreased survival only beyond 60 days, 5 whereas another Taiwanese study indicated that a DTI beyond 20 days increased mortality risk. 6 However, these cohorts comprised a heterogeneous mix of patients who received nonsurgical and surgical treatments, with and without radiation, and without certainty of whether therapy was completed. In addition, no adjustment was made for other treatment intervals, which we demonstrate as pivotal (Fig. 2 , Supporting Fig. 2 ). These differences in methodology likely account for the contrasting results observed in our study. Moreover, patients with early stage disease (11.5% of our cohort) did not perform disproportionately worse with DTI delays, suggesting that presumed stage progression from delays does not impair survival at a population level. Although a massive DTI delay should practically confer risk, we excluded patients who had a DTI >1 year to avoid the influence of extreme outliers on our analysis. Our results appear to offer flexibility to complete time-consuming but valuable treatmentplanning tasks, such as multidisciplinary tumor board discussions, ancillary service evaluations, second opinions at other institutions, and transfers to tertiary specialized centers.
Several caveats deserve mention, including the observational design of the current study and the lack of information on disease-specific survival. The results may not fully translate to patients who receive definitive chemoradiation or those who undergo surgery but do not receive radiation. It is conceivable that patients with poor performance status or aggressive tumors ("bad actors") may be more prone to treatment delays and could drive poorer outcomes: this remains difficult to correct for outside of our adjustment for comorbidity index and TNM stage. Likewise, patients who had particularly aggressive disease fell outside our strict criteria if they could not finish treatment; although their subtherapeutic regimens would confound the analysis (by having paradoxically shortened treatment intervals), the significance of our findings for this subgroup remains unknown. Finally, certain factors correlating with outcome, including smoking status, chemotherapy type, perineural invasion, and recurrence status, were not available and may have some degree of unmeasured impact. Nonetheless, we believe that our current results are the strongest and most relevant to date for characterizing the relative impact of treatment delays on patients with head and neck cancer.
In summary, protracted postoperative and radiation intervals significantly impair the survival of patients with HNSCC who complete surgery and a full course of radiation, with escalating mortality bounded inside specific windows of time. Despite the harm imparted by treatment delays, only a minority of patients completed treatment within the optimal treatment package time window. Delays in treatment initiation, conversely, fail to influence survival when considered in concert with other phases. Taken in perspective, the mortality risk conferred by delayed treatment package time is similar in magnitude to the benefit from therapeutic factors like concomitant chemotherapy, which enjoys wide acceptance for high-risk patients. The meaningful hazard from treatment delays supports the critical importance of efficient interdisciplinary coordination as a therapeutic modality, to anticipate setbacks and address them as aggressively as the cancer itself. Such a focus may yield an underestimated opportunity to streamline management and advance patient outcomes.
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